English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17775/20116 (88%)
Visitors : 9534381      Online Users : 333
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32502


    標題: Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study
    作者: Hung, Peir-Haur
    Yeh, Chih-Ching
    Sung, Fung-Chang
    Hsiao, Chih-Yen
    Muo, Chih-Hsin
    Hung, Kuan-Yu
    Tsai, Kuen-Jer
    貢獻者: Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med
    Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth
    Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth
    China Med Univ, Dept Publ Hlth
    China Med Univ Hosp, Management Off Hlth Data
    China Med Univ, Coll Med, Sch Med, Grad Inst Clin Med Sci
    Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Internal Med
    Natl Cheng Kung Univ, Coll Med, Inst Clin Med
    Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Ctr Clin Med
    關鍵字: Alzheimer's disease
    erythropoietin
    end-stage renal disease
    hemodialysis
    日期: 2019
    上傳時間: 2020-07-29 13:47:36 (UTC+8)
    出版者: IMPACT JOURNALS LLC
    摘要: Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.
    關聯: Aging-Us, v.11, n.17, pp.
    Appears in Collections:[生活應用與保健系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML145View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback